| Zacks Company Profile for Jaguar Animal Health, Inc. (JAGX : NSDQ) |
|
|
| |
| • Company Description |
| Jaguar Health, Inc. is a natural-products pharmaceuticals company. It focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals. The company through its subsidiary Napo Pharmaceuticals Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals. Its product pipeline consists of Mytesi(R), Canalevia(TM), Equilevia(TM) and Neonorm (TM). Jaguar Health Inc., formerly known as Jaguar Animal Health Inc., is based in San Francisco, United States.
Number of Employees: 49 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $2.63 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 75,477 shares |
| Shares Outstanding: 1.02 (millions) |
| Market Capitalization: $2.68 (millions) |
| Beta: 0.56 |
| 52 Week High: $110.75 |
| 52 Week Low: $2.43 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-31.33% |
-33.90% |
| 12 Week |
-52.27% |
-59.85% |
| Year To Date |
-89.58% |
-90.25% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
200 PINE STREET SUITE 400
-
SAN FRANCISCO,CA 94104
USA |
ph: 415-371-8300
fax: - |
None |
None |
|
|
| |
| • General Corporate Information |
Officers
Lisa A. Conte - Chief Executive Officer; President and Director
James J. Bochnowski - Chairman of the Board
Carol Lizak - Chief Financial Officer and Treasurer
John Micek - Director
Jonathan B. Siegel - Director
|
|
Peer Information
Jaguar Animal Health, Inc. (GSAC)
Jaguar Animal Health, Inc. (CASI)
Jaguar Animal Health, Inc. (ALCD.)
Jaguar Animal Health, Inc. (OMNN)
Jaguar Animal Health, Inc. (CGPI.)
Jaguar Animal Health, Inc. (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 47010C888
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/12/25
|
|
Share - Related Items
Shares Outstanding: 1.02
Most Recent Split Date: 3.00 (0.04:1)
Beta: 0.56
Market Capitalization: $2.68 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-23.81 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 1.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/12/25 |
|
|
|
| |
